Missing: Sentinel Oncology's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Sentinel Oncology's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Sentinel Oncology
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Sentinel Oncology is included in 1 Expert Collection, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Sentinel Oncology Patents
Sentinel Oncology has filed 10 patents.
Experimental cancer drugs, Transcription factors, Proteins, Pyridines, Clusters of differentiation
Experimental cancer drugs, Transcription factors, Proteins, Pyridines, Clusters of differentiation
Latest Sentinel Oncology News
Sep 2, 2021
September 02, 2021 09:00 AM Eastern Daylight Time PRINCETON, N.J.--( BUSINESS WIRE )--The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces today that it has entered an agreement with Sentinel Oncology (Sentinel), a drug discovery company. The McQuade Center for Strategic Research and Development at Otsuka in the U.S. will support the clinical development of a first-in-class therapeutic with the potential to treat Fragile X syndrome (FXS), a rare, genetic condition that causes intellectual disability, behavioral and learning challenges, and various physical characteristics1. Under the terms of the agreement, MSRD and Sentinel will collaborate to support the Phase 1a and Phase 1b clinical trials for Sentinel’s investigational compound SOL784 with the opportunity to expand the collaboration after those studies. “Although there are treatment options for the symptoms of Fragile X syndrome available today, none have been approved by regulatory authorities to address the underlying cause of this rare genetic disorder,” said Robert McQuade, PhD, president, McQuade Center for Strategic Research and Development, LLC, and chief strategic officer, Otsuka Pharmaceutical Development & Commercialization, Inc. “Our two organizations share like-minded missions of delivering treatments to patients with unmet medical needs. We are hopeful that our collaboration can lead to the development of a potential therapeutic for people living with this condition.” “We are delighted to be collaborating with the MSRD team to advance SOL784 into clinical development” said Robert G Boyle, founder and CEO of Sentinel Oncology. “SOL784 targets the underlying disease biology of FXS and we are excited for the prospects of a drug which has the potential to provide real benefits to patients for whom there is an unmet medical need” About Fragile X Syndrome Fragile X syndrome (FXS) is a rare, genetic condition that causes intellectual disability, behavioral and learning challenges, and various physical characteristics. Though FXS occurs in both genders, males are more frequently affected than females, and generally with greater severity. FXS has been detected in all populations and ethnic groups. While researchers do not have an exact number for how many Americans (males and females) could have full-mutation Fragile X syndrome, estimates range between as few as 38,000 to as high as 87,000 people living with the condition.1 About Sentinel Oncology Sentinel Oncology is a drug discovery company dedicated to the development of novel therapeutics to treat patients for whom there is currently an unmet medical need. The company has a focus on Neuro-Oncology with a suite of brain penetrant drug candidates and a mission to increase survival and improve outcomes for cancer patients with CNS tumours. About McQuade Center for Strategic Research and Development (MSRD) Established in 2019 by the Otsuka pharmaceutical business in the U.S., the mission of MSRD is to search for, identify, and fund innovative early-stage research and development programs that have the potential to build the future portfolio of Otsuka products. Otsuka is dedicated to investing in innovative and creative products in areas of unmet need and MSRD was created as an extension of this commitment to support and identify early-stage opportunities that can change the landscape of treatments for mental illness and renal disorders. For more information, please visit https://msrd-us.com/ . About Otsuka Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal, and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does. Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies’ 1,700 employees in the U.S. develop and commercialize medicines in the areas of mental health, nephrology, and cardiology, using cutting-edge technology to address unmet healthcare needs. OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Company, Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 47,000 people worldwide and had consolidated sales of approximately USD 13.3 billion in 2020. All Otsuka stories start by taking the road less traveled. Learn more about Otsuka in the U.S. at www.otsuka-us.com and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.’s global website is accessible at www.otsuka.co.jp/en/ .
Sentinel Oncology Frequently Asked Questions (FAQ)
When was Sentinel Oncology founded?
Sentinel Oncology was founded in 2005.
What is Sentinel Oncology's latest funding round?
Sentinel Oncology's latest funding round is Other Investors.
Who are the investors of Sentinel Oncology?
Investors of Sentinel Oncology include Cambridge Enterprise Seed Funds.
Who are Sentinel Oncology's competitors?
Competitors of Sentinel Oncology include Forma Therapeutics, Echelon Biosciences, Terpenoid Therapeutics, BrightPath Biotherapeutics, Astex Pharmaceuticals (acquired by SuperGen) and 11 more.
Compare Sentinel Oncology to Competitors
Advanced Cancer Therapeutics engages in the discovery, development, manufacture, and commercialization of cancer therapeutics.
IIT Research Institute (IITRI) is a contract research organization (CRO) that aims to provide non-clinical toxicology and other drug development services to government and industry. IITRI offers particular expertise in oncologics drug development, inhalation toxicology and technology, carcinogenesis and cancer prevention, and biodefense. IITRI's Drug Discovery Division is a research-based group whose focus is the design and synthesis of new small molecule therapeutics for cancer and infectious disease.
De Novo Pharmaceuticals Ltd is a computationally-based drug discovery company focused on small molecule therapeutics. De Novo develops a suite of structure-generating programs called SkelGen. The core algorithm generates new molecular structures by the random assembly of small molecular fragments in situ. Ninety-percent of the structures produced by SkelGen is chemically tractable.
Medicor Biosciences, founded in 2006 is a development-stage company focused on drug discovery for combating cancer. The founding scientists are leaders in a class of anti-hormone drugs that are designed to block the relaxin hormone cellular signaling pathways in a number of different cancer types. Using the company's Relaxofen technology platform, therapeutic candidates are generated by engineering the natural relaxin peptide to display antagonistic properties. Through pre-clinical development and clinical trials, Medicor Biosciences plans to develop and potentially license the technology so that the therapeutics can be available for cancer patients as an anti-hormone therapy to impair the growth and spread of the disease.
AndroScience intends to use its expertise in natural product chemistry to discover compounds that target at different stages of the androgen activation pathway, and to develop lead compounds into new medicines for acne, androgenetic alopecia, wound healing, benign prostatic hyperplasia, prostate cancer and for other androgen or androgen receptor-related disorders.
LEAD Therapeutics, Inc. is a chemistry-driven drug discovery company focused on delivering novel and differentiated small molecule pre-IND candidates against clinically validated therapeutic targets by leveraging the best of the US and China. Headquartered in the San Francisco Bay Area, LEAD Therapeutics is led by an experienced small molecule drug discovery team with proven track records in the pharmaceutical and biotech industries. The company plans to carry out the majority of its discovery research activities in China.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.